|
|
Post by lakon on Sept 7, 2017 10:34:05 GMT -5
I'm thinking about taking a longer MNKD position and a short against a basket of overpriced BP and biotech, e.g. LLY, NKTR, NVO, SNY, and eventually ORMP.
The mechanics are simple. The others are not likely to double anytime soon and are probably peaking. MNKD can be pushed around, and it might double soon...
|
|
|
|
Post by dreamboatcruise on Sept 7, 2017 10:50:50 GMT -5
I'm thinking about taking a longer MNKD position and a short against a basket of overpriced BP and biotech, e.g. LLY, NKTR, NVO, SNY, and eventually ORMP. The mechanics are simple. The others are not likely to double anytime soon and are probably peaking. MNKD can be pushed around, and it might double soon... High risk, high reward type of play. If MNKD really does take off I don't think a pharma downturn would kill its price appreciation so I'd view the short as more of a separate bet than as a hedge for the MNKD play. Each of those bets has a fair amount of risk involved. I learned my lesson on shorting when I shorted some of the severely overpriced dotcoms pre 2000... and they went on to become super severely overpriced. It can be tough betting against a hot sector. Shorting is more often successful when its used against a small company with financial difficulties  |
|
|
|
Post by agedhippie on Sept 7, 2017 19:16:37 GMT -5
I'm thinking about taking a longer MNKD position and a short against a basket of overpriced BP and biotech, e.g. LLY, NKTR, NVO, SNY, and eventually ORMP. The mechanics are simple. The others are not likely to double anytime soon and are probably peaking. MNKD can be pushed around, and it might double soon... High risk, high reward type of play. If MNKD really does take off I don't think a pharma downturn would kill its price appreciation so I'd view the short as more of a separate bet than as a hedge for the MNKD play. Each of those bets has a fair amount of risk involved. I learned my lesson on shorting when I shorted some of the severely overpriced dotcoms pre 2000... and they went on to become super severely overpriced. It can be tough betting against a hot sector. Shorting is more often successful when its used against a small company with financial difficulties Same reason why I never short stocks - the market can remain irrational longer than you can remain solvent. If they really want to do it though I would short XPH (pharma sector ETF) rather than individual stock. |
|
|
|
Post by falconquest on Sept 7, 2017 19:45:18 GMT -5
I'm thinking about taking a longer MNKD position and a short against a basket of overpriced BP and biotech, e.g. LLY, NKTR, NVO, SNY, and eventually ORMP. The mechanics are simple. The others are not likely to double anytime soon and are probably peaking. MNKD can be pushed around, and it might double soon... Too late, it already doubled. |
|
|
|
Post by cjm18 on Sept 7, 2017 22:04:47 GMT -5
Insanely high short interest in mnkd past few days. Today more so. Only a hand full of times has it been this bad since beginning of 2016. Short term bearish. Long term bullish.
We are in a bull market As long as the one year return on the S and p is beating t bills. The one year return on international funds is beating the s and p. I'm in 100% international funds. I.e. Ixus.
|
|
